{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:13:29Z","timestamp":1786997609761,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.transci.2020.102950","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:12:55Z","timestamp":1601021575000},"page":"102950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["RhIg for the prevention Rh immunization and IVIg for the treatment of affected neonates"],"prefix":"10.1016","volume":"59","author":[{"given":"Tobias J.","family":"Legler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 18","key":"10.1016\/j.transci.2020.102950_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1471-0528.1998.tb10286.x","article-title":"The scientific basis of antenatal prophylaxis","volume":"105","author":"Urbaniak","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.transci.2020.102950_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/tme.12099","article-title":"Anti-D prophylaxis: past, present and future","volume":"24","author":"Haas","year":"2014","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2020.102950_bib0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1537-2995.2000.40040428.x","article-title":"Primary anti-D immunization by weak D type 2 RBCs","volume":"40","author":"Flegel","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.0041-1132.2005.04256.x","article-title":"Anti-D immunization by DEL red blood cells","volume":"45","author":"Wagner","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0025","first-page":"623","article-title":"Rh isoimmunization during pregnancy: antenatal prophylaxis","volume":"118","author":"Bowman","year":"1978","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.transci.2020.102950_bib0030","first-page":"204","article-title":"Die Rhesusprophylaxe \u2013 Geschichte und aktueller Stand","volume":"119","author":"Behrens","year":"1997","journal-title":"Zentralbl Gyn\u00e4kol"},{"key":"10.1016\/j.transci.2020.102950_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2393-14-87","article-title":"Routine administration of anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice","volume":"14","author":"Kent","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.transci.2020.102950_bib0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/01443610701469941","article-title":"The safety of RhIG in the prevention of haemolytic disease of the newborn","volume":"27","author":"Hirose","year":"2007","journal-title":"J Obstet Gynaecol"},{"issue":"February (2)","key":"10.1016\/j.transci.2020.102950_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000020.pub2","article-title":"Anti-D administration in pregnancy for preventing Rhesus alloimmunisation","volume":"28","author":"Crowther","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2020.102950_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1423-0410.2007.00945.x","article-title":"Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers","volume":"93","author":"Kumpel","year":"2007","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.transci.2020.102950_bib0055","article-title":"Anti-D administration after childbirth for preventing Rhesus alloimmunisation","author":"Crowther","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2020.102950_bib0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/tme.12091","article-title":"BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn","volume":"24","author":"Qureshi","year":"2014","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2020.102950_bib0065","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1537-2995.2011.03536.x","article-title":"Fetomaternal hemorrhage in normal vaginal delivery and in delivery by cesarean section","volume":"52","author":"Lubusky","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0070","doi-asserted-by":"crossref","first-page":"i5789","DOI":"10.1136\/bmj.i5789","article-title":"Sensitivity of fetal RHDscreening for safe guidance of targeted anti-D immunoblobulin prophylaxis: Prospective cohort study of a nation-wide programme in the Netherlands","volume":"355","author":"De Haas","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.transci.2020.102950_bib0075","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/j.1537-2995.2008.01843.x","article-title":"The determination of the fetal RhD status from maternal plasma for decision making on Rh prophylaxis is feasible","volume":"48","author":"M\u00fcller","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0080","first-page":"1","article-title":"Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care","volume":"32","author":"Clausen","year":"2014","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.transci.2020.102950_bib0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0887-7963(88)70039-5","article-title":"The prevention of Rh immunization","volume":"2","author":"Bowman","year":"1988","journal-title":"Transf Med Rev"},{"key":"10.1016\/j.transci.2020.102950_bib0090","doi-asserted-by":"crossref","first-page":"e30711","DOI":"10.1371\/journal.pone.0030711","article-title":"Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analysis adjusted for differences in study design and quality","volume":"2","author":"Turner","year":"2012","journal-title":"PLoS One"},{"issue":"83","key":"10.1016\/j.transci.2020.102950_bib0095","article-title":"Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review","volume":"20","author":"Runkel","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.transci.2020.102950_bib0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12916-019-1254-4","article-title":"High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis","volume":"17","author":"Yang","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.transci.2020.102950_bib0105","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/pd.4419","article-title":"Routine non-invasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women \u2013 2 years of screening experience from Denmark","volume":"34","author":"Clausen","year":"2014","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.transci.2020.102950_bib0110","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/aogs.13191","article-title":"Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women \u2013 outcome of the first two years of a national program in Finland","volume":"96","author":"Haimila","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.transci.2020.102950_bib0115","series-title":"High-throughput non-invasive prenatal testing for fetal RHD genotype","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"10.1016\/j.transci.2020.102950_bib0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jogc.2016.12.006","article-title":"SkollA. No. 343-Routine non-invasive prenatal prediction of fetal RHD genotype in Canada: the time is here","volume":"39","author":"Johnson","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.transci.2020.102950_bib0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1537-2995.2007.01533.x","article-title":"Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium","volume":"48","author":"Minon","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/AOG.0b013e31825d33d9","article-title":"Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy","volume":"120","author":"Wikman","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"February","key":"10.1016\/j.transci.2020.102950_bib0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tracli.2018.05.001","article-title":"Relevance and costs of RHD genotyping in women with a weak D phenotype","volume":"26","author":"Laget","year":"2019","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2020.102950_bib0140","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/pd.2889","article-title":"Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days","volume":"31","author":"M\u00fcller","year":"2011","journal-title":"Prenat Diagn"},{"issue":"October (10)","key":"10.1016\/j.transci.2020.102950_bib0145","doi-asserted-by":"crossref","first-page":"e76990","DOI":"10.1371\/journal.pone.0076990","article-title":"Pre-Analytical conditions in non-invasive prenatal testing of cell-free fetal RHD","volume":"8","author":"Clausen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.transci.2020.102950_bib0150","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14737159.2018.1461562","article-title":"Lessons learned from the implementation of non-invaisve fetal RHD screening","volume":"18","author":"Clausen","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.transci.2020.102950_bib0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejogrb.2012.02.001","article-title":"Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study","volume":"162","author":"Benachi","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.transci.2020.102950_bib0160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cca.2011.11.004","article-title":"Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving","volume":"413","author":"Macher","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.transci.2020.102950_bib0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/uog.14723","article-title":"Costs and benefits of non-invasive fetal RhD determination","volume":"45","author":"Teitelbaum","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.transci.2020.102950_bib0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/trf.15631","article-title":"Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non-D and non-K-alloimmunized pregnancies","volume":"60","author":"Koelewijn","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102950_bib0175","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pd.5355","article-title":"The near disappearance of fetal hydrops in relation to current state-of-the-art managemant of red cell alloimmunization","volume":"38","author":"Zwiers","year":"2018","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.transci.2020.102950_bib0180","first-page":"129","article-title":"Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven","volume":"7","author":"Pasman","year":"2015","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1016\/j.transci.2020.102950_bib0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ajog.2004.06.063","article-title":"Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization","volume":"192","author":"Van Kamp","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.transci.2020.102950_bib0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000490154","article-title":"Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells","volume":"45","author":"Mayer","year":"2018","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2020.102950_bib0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2017.1331124","article-title":"Neonatal management and outcome in alloimmune hemolytic disease","volume":"10","author":"Ree","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.transci.2020.102950_bib0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Cllin Immunol"},{"key":"10.1016\/j.transci.2020.102950_bib0205","article-title":"Immunoglobulin for alloimmune hemolytic disease in neonates","volume":"18","author":"Zwiers","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2020.102950_bib0210","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1542\/peds.2010-3242","article-title":"Intravenous immunoglobin in neonates with Rhesus hemolytic disease: A randomized controlled trial","volume":"127","author":"VEHJ","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.transci.2020.102950_bib0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1537-2995.2012.03827.x","article-title":"The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial","volume":"53","author":"Santos","year":"2013","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2020.102950_bib0220","article-title":"On the dark side of therapies with immunoglobulin concentrates: the adverse events","volume":"6","author":"Sp\u00e4th","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2020.102950_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1542\/peds.2009-0676","article-title":"Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease","volume":"125","author":"Figueras-Aloy","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.transci.2020.102950_bib0230","doi-asserted-by":"crossref","first-page":"F325","DOI":"10.1136\/archdischild-2013-304878","article-title":"Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis","volume":"99","author":"Louis","year":"2014","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.transci.2020.102950_bib0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-3476(05)82551-X","article-title":"High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease","volume":"121","author":"R\u00fcbo","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.transci.2020.102950_bib0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/030006059502300406","article-title":"High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease","volume":"23","author":"Dgoglu","year":"1995","journal-title":"J Int Med Res"},{"key":"10.1016\/j.transci.2020.102950_bib0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1651-2227.1999.tb01085.x","article-title":"High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice","volume":"88","author":"Alpay","year":"1999","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.transci.2020.102950_bib0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/tropej\/47.1.50","article-title":"Multiple dose IVIg treatment in neonatal Immune hemolytic jaundice","volume":"47","author":"Tanyer","year":"2001","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.transci.2020.102950_bib0255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/jmf.16.3.163.166","article-title":"Intravenous immuoglobuin G (IVIg) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn","volume":"16","author":"Miqdad","year":"2004","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.transci.2020.102950_bib0260","first-page":"1827","article-title":"Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn","volume":"27","author":"Nasseri","year":"2006","journal-title":"Saudi Med J"},{"key":"10.1016\/j.transci.2020.102950_bib0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00431-010-1310-8","article-title":"Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn \u2013 a prospective randomized controlled trial","volume":"170","author":"Elalfy","year":"2011","journal-title":"Eur J Pediatr"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:52:25Z","timestamp":1761468745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220302664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1473050220302664"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102950","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RhIg for the prevention Rh immunization and IVIg for the treatment of affected neonates","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102950"}}